Reuters: PPD looks for sale or IPO at $7B-$8B; In eye of the storm, Valeant brings in crisis management talent;

@FierceBiotech: ICYMI Friday: AstraZeneca looks to bag Imbruvica rival in $5B-plus Acerta buyout: Report. More | Follow @FierceBiotech

@JohnCFierce: Mitsubishi Tanabe backs Akebia PhIII with a $350M Asian deal for vadadustat. Report | Follow @JohnCFierce

@DamianFierce: The 2015 Biotech IPO Boom, in Requiem. Watch | Follow @DamianFierce

> Reuters reported that the private equity groups behind the big CRO PPD are looking to either sell the company or take it public in an IPO that would value the company at between $7 billion and $8 billion. Report

> Hammered by reports over its pricing strategies and ties to an aggressive specialty pharma, Valeant has reportedly done an about face and brought in crisis management expertise to help steer it way through the controversy. Report

Medical Device News

@FierceMedDev: ICYMI: Bloomberg: Embattled Theranos CEO continues to beat the 'transparency' drum. Report | Follow @FierceMedDev

@EmilyWFierce: Lab experts lash out at FDA move to beef up regulation of lab-developed tests. Article | Follow @EmilyWFierce

> St. Jude touts new forms of neurostimulation at Neuromodulation Society meeting. More

> WuXi leads $30M for startup to back Dx for personalized cardio, oncology drug regimens. Article

> App-based glucose monitor implant startup Senseonics reverse-merges to go public in anticipation of CE mark. Story

Pharma News

@FiercePharma: Veterinarians debate necessity of dog flu vaccines from Merck and Zoetis. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI Friday: NICE backs Astellas' Xtandi in pre-chemo patients, but J&J's Zytiga isn't so lucky. Article | Follow @CarlyHFierce

> Icahn: Change the international tax code, and Pfizer will drop its 'travesty' of a merger. More

> Lilly's price for Portrazza way too high for its limited benefit in lung cancer, doctors say. Article

Pharma Marketing News

> Roche challenges hometown rival Novartis with new targeted lung-cancer med Alecensa. Item

> Shire finally gets Baxalta to the deal-talks table. Article

> Novo Nordisk eyes stepped-up diabetes care in 'beyond the pill' deal with IBM Watson. Story

> Pharma comics partner Medikidz aims to be a child health superhero. Report

> BMS' Opdivo repeats, new flu ads join list of top pharma ad spending for November. More

Animal Health News

> Cornell scientists create first litter of puppies through in vitro fertilization. News

> Report: Antibiotic sales for food animals still on the rise, despite FDA restrictions. Item

> U.K.-based Genus teams with U.S. scientists to create pigs resistant to deadly virus. Story

> Veterinarians debate necessity of dog flu vaccines from Merck and Zoetis. More

> Lilly separates animal health manufacturing but insists it's not prepping a spinoff. Article

Biotech IT News

> GoBalto lands global site activation software deal with Icon. More

> Academics snag EU cash for 3-D genomics project. Report

> SAP makes pitch for precision medicine market with a pair of products. Item

> Analyst: Use of tech to streamline clinical trials 'still early in its adoption cycle.' Story

> Illumina invests in CRISPR gene editing software player. Article

Suggested Articles

Novartis is ending early discovery at its R&D site in Shanghai to “rebalance” its discovery and early development efforts.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year.